Tunlametinib

Inquire / Price
  • Model Number:
    RL23202402
  • Brand Name:
    科露平
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    56c/bottles
  • Strength
    3mg
  • Compositon
    Tunlametinib
  • Treatment
    Advanced melanoma harboring NRAS mutations
  • Form
    capsule
  • Brand
    科露平
  • Quantity Unit
    3mg*56c/Box
  • Manufacturer
    Shanghai KeChow Pharma, Inc.,China

Tunlametinib (HL-085)  is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor, for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas. 

  • Tunlametinib sold under the brand name 科露平® in china.

March 18, 2024, China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy.


Link

Poster

Top